InvestorsHub Logo
Post# of 253163
Next 10
Followers 840
Posts 120472
Boards Moderated 18
Alias Born 09/05/2002

Re: jbog post# 214405

Sunday, 12/10/2017 4:01:13 PM

Sunday, December 10, 2017 4:01:13 PM

Post# of 253163
(GILD/NVS/etc)—NEJM editorial on the state of CAR-T:

http://www.nejm.org/doi/full/10.1056/NEJMe1714680

The final paragraph speaks to the shortcomings of existing CAR-T designs in solid tumors and the promise of targeting neoantigens to overcome these limitations:

CAR-engineered T cells are a revolutionary treatment for patients with advanced blood cancers. Unfortunately, CAR-engineered T cells have been largely ineffective in patients with metastatic solid cancers, which account for the majority of cancer-related deaths. One major factor contributing to this lack of efficacy is the paucity of suitable cell-surface molecules that are expressed by solid cancers for CARs to target.

This roadblock can be overcome by engineering T cells with T-cell receptors that can recognize tumor-specific antigens derived from intracellular proteins, such as neoantigens arising as a consequence of somatic mutations expressed by tumors, which are found in the majority of patients with metastatic epithelial cancers. T cells that are genetically modified to express T-cell receptors targeting mutated neoantigens may represent a new wave of promising and highly personalized gene-engineered T-cell therapies for patients with metastatic solid cancers.


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.